Compugen | CGEN - Selling And Administration Expenses


Compugen reported $2.21M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Arca Biopharma USD 2.23M 1.08M Dec/2025
aTyr Pharma USD 82.26M 77.46M Dec/2025
Bio Path USD 199K 300K Sep/2025
Brainstorm Cell Therapeutics USD 1.39M 326K Dec/2025
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
Immunic USD 3.45M 451K Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
RedHill Biopharma USD 4.48M 1.52M Mar/2024
TherapeuticsMD USD 1.23M 90K Jun/2024